Abstract Number: 2032 • ACR Convergence 2020
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…Abstract Number: 0363 • ACR Convergence 2020
Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status
Background/Purpose: Ixekizumab (IXE), a high-affinity anti-interleukin-17A monoclonal antibody, is effective in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA), who had elevated C-reactive protein (CRP)…Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…Abstract Number: 1309 • ACR Convergence 2020
Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Inflammatory Bowel Disease: A Secondary Care Cross-Sectional Study
Background/Purpose: Axial spondyloarthritis (axSpA) is closely related to inflammatory bowel disease (IBD), however contemporary data on the burden of hidden disease in the IBD population…Abstract Number: 1358 • ACR Convergence 2020
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…Abstract Number: 1592 • ACR Convergence 2020
Improving Documentation of Smoking Cessation Counseling Among Spondyloarthropathy Smokers
Background/Purpose: Smoking is prevalent among patients with spondyloarthropathies (SpA) and is associated with higher disease activity, poorer quality of life, and dampened response to biologic…Abstract Number: 1870 • ACR Convergence 2020
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Background/Purpose: The lack of pediatric classification criteria for axial disease is a major impediment to the conduct of clinical trials for juvenile spondyloarthritis (SpA). Classification…Abstract Number: 1902 • ACR Convergence 2020
Determinants of Physician Global Assessment and Influence of Contextual Factors in Early Axial Spondyloarthritis
Background/Purpose: In rheumatic and musculoskeletal diseases, physician global assessment (PhGA) is a major factor of treatment decision. However, it is not well-known which disease manifestations…Abstract Number: 0364 • ACR Convergence 2020
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) report pain (70–80%), stiffness (20–40%), and fatigue (50–60%) as the most troubling symptoms. Early diagnosis and sustained improvement…Abstract Number: 0882 • ACR Convergence 2020
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key…Abstract Number: 1310 • ACR Convergence 2020
Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
Background/Purpose: Multiple studies have confirmed that the gut and stool microbiome in ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are distinct from healthy controls,…Abstract Number: 1360 • ACR Convergence 2020
New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study
Background/Purpose: A warning regarding safety of Interleukin 17 inhibitors (IL-17i) has been issued from data of randomized controlled trials (RCT) showing cases of new-onset inflammatory bowel…Abstract Number: 1603 • ACR Convergence 2020
P4 Index Correlates with RAPID3 and Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA)
Background/Purpose: RAPID3 scores correlate well with disease-specific indices, including the Clinical Disease Activity Index (CDAI) in RA and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)…Abstract Number: 1871 • ACR Convergence 2020
Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
Background/Purpose: The aim of this study was to compare work-productivity and activity impairment outcomes after two-year follow-up between chronic back pain (CBP) patients with and…Abstract Number: 1903 • ACR Convergence 2020
Assessment of Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis : Preliminary Results
Background/Purpose: Axial spondyloarthritis (ax-SpA) corresponds to a group of chronic inflammatory disease mainly affecting the axial skeleton. TNF and IL-17A have been identified as key…
ACR Meeting Abstracts